Results 131 to 140 of about 41,518 (220)

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

JEADV Clinical Practice, Volume 5, Issue 1, Page 205-210, March 2026.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon, Karishma S. Shah, Sidharth Chand, Bonnie Lee, Janellen Smith, Michelle S. Min   +5 more
wiley   +1 more source

Inflammatory Bowel Diseases Are Not Associated with an Increased Risk of Autoimmune Thyroiditis. [PDF]

Med Sci (Basel)
Barton A, Labenz C, Grabbe S, Schattenberg JM, Kaps L, Kostev K.   +5 more
europepmc   +1 more source

Preoperative VEGFR‐TKI Plus ICI Therapy Facilitates 3D‐Guided Cytoreductive Nephron‐Sparing Surgical Feasibility and Immune Remodeling in Advanced Renal Cell Carcinoma

Med Research, Volume 2, Issue 1, Page 89-105, March 2026.
Preoperative VEGFR‐TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment remodeling. These immunologic changes improve the feasibility of 3D reconstruction‐guided robotic cytoreductive nephron‐sparing surgery, resulting in reduced
Wenhao Xu, Aihetaimujiang Anwaier, Qintao Ge, Siqi Zhou, Xi Tian, Shuxuan Zhu, Guohai Shi, Yu Zhu, Dingwei Ye, Mierxiati Abudurexiti, Hailiang Zhang   +10 more
wiley   +1 more source

Insulin Autoimmune Syndrome Associated With Hashimoto Thyroiditis and Nodular Thyroid Disease: Clinical Management With Flash Glucose Monitoring and Prednisolone Therapy. [PDF]

Am J Case Rep
Nowak A, Morawiec-Sławek K, Motyka M, Trofimiuk-Müldner M, Hubalewska-Dydejczyk A.   +4 more
europepmc   +1 more source

IgG4‐Related Lung Disease in a Former Smoker: A Challenging Diagnosis

Respirology Case Reports, Volume 14, Issue 3, March 2026.
This case highlights the importance of a structured and comprehensive diagnostic approach for patients with complex clinical presentations. It also demonstrates the potential role of rituximab therapy in treating IgG4 disease. ABSTRACT Immunoglobulin G4‐related disease (IgG4‐RD) is a rare systemic fibroinflammatory condition that may affect virtually ...
Serena Bellani, Federica Pezzuto, Davide Garbin, Beatrice Scapolan, Luisa Santomartino, Fiorella Calabrese, Elisabetta Balestro, Nicol Bernardinello   +7 more
wiley   +1 more source

Chronic Lymphocytic Thyroiditis (Hashimoto Thyroiditis) [PDF]

Ear, Nose & Throat Journal, 2014
openaire   +2 more sources

Elevated beta‐hydroxybutyrate within a pediatric population and its associated pathology: A retrospective case series

Journal of Forensic Sciences, Volume 71, Issue 2, Page 837-845, March 2026.
Abstract Elevated beta‐hydroxybutyrate (BHB) is a marker for ketoacidosis. Post‐mortem values for the diagnosis of fatal ketoacidosis and the associated clinical and histologic findings are limited in the pediatric population. A retrospective case series of pediatric autopsy records and histology slides was conducted.
Nasim Haghandish, Anthea Girdwood, Christopher Milroy, Jacqueline Parai   +3 more
wiley   +1 more source

Riedel thyroiditis secondary to papillary thyroid carcinoma: A case report. [PDF]

Medicine (Baltimore)
Zhao T, Wang S, Zhang M.
europepmc   +1 more source

Bridging FDA Adverse Event Reporting System (FAERS) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients

Thoracic Cancer, Volume 17, Issue 6, March 2026.
Elderly lung cancer patients face increased risks of severe and fatal AEs during ICIs treatment. Reports concerning males, Asians, and anti‐PD‐1 recipients were associated with higher odds of a fatal outcome. Immune‐mediated pneumonitis is the most frequently reported severe AE, calling for heightened vigilance for these high‐risk subgroups.
Yumeng Tian, Xin Nie, Yue Yuan, Qian Wei, SiQi Zhang, Lin Li   +5 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source